GivBux posts revenue gains but $5.55M derivative hit fuels $6.63M net loss, warns going concern

GivBux, Inc (PINK: GBUX) - quick operating and income-statement snapshot.

Headline summary
GivBux reported revenue growth year-over-year but recorded very large non‑cash losses that drove a steep net loss and widened stockholders' deficit. The company flagged a going concern and material internal-control weaknesses. Key short-term risks: massive derivative/warrant liabilities, heavy convertible note activity, thin cash and current‑liability overload.

Key facts & figures (as reported)
* Cash: $18,157 (June 30, 2025).
* Current assets: $118,837; Total assets: $140,705 (June 30, 2025).
* Current liabilities: $9,080,408 (June 30, 2025).
* Current liabilities exceed current assets by $8,961,571 (company disclosure).
* Total derivative liabilities: $5,951,887 (June 30, 2025) vs $319,337 (Dec 31, 2024).
* Convertible notes - carrying amount: $1,316,310; unamortized discount: $(605,514); net recorded convertible notes payable: $710,796.
* Loans payable: $525,150. Nine (9) loans in default with unpaid balance of $304,000 (June 30, 2025).
* Shares outstanding: 94,851,733 (June 30, 2025).
* Accumulated deficit: $(36,732,878); Total stockholders' deficit: $(8,939,703) (June 30, 2025).

Income statement - key metrics
* Revenue - three months ended 6/30/25: $55,803 vs $25,030 (3mo 6/30/24). Six months ended 6/30/25: $121,826 vs $72,399 (6mo 2024).
* Cost of revenue - 3mo: $39,434; 6mo: $94,584.
* Gross profit - 3mo: $16,369 vs $25,030 prior; 6mo: $27,242 vs $72,399 prior.
* Total operating expenses - 3mo: $553,950 vs $2,600,178 prior; 6mo: $748,343 vs $2,744,733 prior.
* Loss from operations - 3mo: $(537,581) vs $(2,575,148) prior; 6mo: $(721,101) vs $(2,672,334) prior.
* Change in fair value of derivative liabilities - 3mo: $(5,320,673); 6mo: $(5,552,522). This is the single largest driver of the period loss.
* Net loss - 3mo: $(6,104,831); 6mo: $(6,631,650).
* Basic & diluted loss per share - 3mo: $(0.06); 6mo: $(0.07).

Positive aspects
* Revenue growth: quarter and six‑month revenue increased vs prior year periods (3mo: $55.8k vs $25.0k; 6mo: $121.8k vs $72.4k).
* Operating expense base declined materially versus the prior year comparative periods (management cites a one‑time $2.274M marketing charge in 2024).
* Gross profit remains positive (non‑zero margins on activity vs prior period mix).

Negative aspects (income‑statement & balance-sheet drivers)
* Massive non‑cash derivative/warrant fair‑value losses - change in fair value of derivative liabilities of $5.32M (3mo) drove the six‑month net loss to $(6.63M).
* Large derivative liability balance: $5.95M recorded as Level 3 fair value; valuation inputs show extreme volatility assumptions (up to 333%).
* Stockholders' deficit deepened to $(8.94M) and accumulated deficit to $(36.73M).
* Liquidity stress: only $18k cash and current liabilities of $9.08M (many convertible notes and loans due within 12 months).
* Heavy dilution risk: recent issuances include warrants and commitment shares; a dividend in the form of warrants was recorded at $23,147,870 (non‑cash) and outstanding warrants total 13,116,256 (fair value reported $28,194,538).
* Defaults: multiple loans and many convertible notes in default (21 convertible notes with unpaid balance $509,229 in default as of 6/30/25).
* Going concern: management states substantial doubt about the company's ability to continue without new equity or debt financing.
* Control & reporting weaknesses: the company disclosed material weaknesses in internal control over financial reporting.

What's happening inside the company - concise view
* Management is pursuing fundraising (convertible note financings, registration and SPA activity were disclosed) and issued new convertible notes and warrants in H1 2025.
* Significant non‑cash derivative and warrant recognition has created a large balance-sheet liability and large accounting losses despite modest operating revenues.
* The company is scaling sales/transactional activity (recruiting sales leaders, beta testing) but remains undercapitalized - cash flow from operations is negative and financing activity is essential to keep operations going.
* The board approved a special warrant dividend (recorded at $23.15M) and entered several financing agreements; closing and documentation issues (e.g., share purchase agreement with Charter House) show execution risk.

Bottom line / watch points
* Watch short-term liquidity and financing outcomes - cash is minimal and current liabilities far exceed current assets.
* Monitor derivative/warrant valuations and any subsequent changes - these drove most of the reported loss and are highly sensitive to valuation inputs.
* Expect dilution risk from convertible note conversions and outstanding warrants; review conversion terms (many have steep discounts to market or fixed low conversion prices).
* Internal-control weaknesses and the going‑concern disclosure increase execution and reporting risk for investors.

If you need a one‑page downloadable summary or a short checklist for due‑diligence on GivBux (PINK: GBUX), I can produce that next.